Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Table 3 shows the results of the correlation between the blood values of Vitamin D and PTH and the demographic and clinical characteristics of the patients.Association of Vitamin D and Parathormone values with socio-demographic and clinical characteristics of the patientsVitamin Dp-valueParathormonep-valueReferenceInsufficiency /DeficiencyHighReferenceDiagnosisHodgkin lymphoma1 (25.0)2 (75.0)0.460 (0.0)3 (100.0)0.56Non-Hodgkin lymphoma4 (16.0)21 (84.0)6 (23.1)20 (76.9)Age63.0 (21.0)66.0 (26.5)0.4962.0 (23.5)77.0 (4.5)0.02GenderMale5 (26.3)14 (73.7)0.145 (26.3)14 (73.7)0.63Female0 (0.0)9 (100.0)1 (10.)9 (90.0)Chemo and steroid therapyYes2 (12.5)14 (87.5)0.636 (37.5)10 (62.5)0.02No3 (23.1)10 (76.9)0 (0)13 (100)ComorbiditiesYes4 (18.2)18 (81.8)0.996 (27.3)16 (72.7)0.15No1 (14.3)6 (85.7)0 (0)7 (100)Vertebral fracturesYes2 (10.5)17 (89.5)0.296 (31.6)13 (68.4)0.05No3 (33.3)6 (66.7)0 (0.0)10 (100)Femoral DEXANormal3 (20.0)12 (80.0)0.833 (20.0)12 (80.0)0.99Osteopenia / Osteoporosis1 (9.1)10 (90.9)3 (25.0)9 (75.0)Vertebral DEXANormal2 (14.3)12 (85.7)0.573 (21.4)11 (78.6)0.93Osteopenia / Osteoporosis3 (23.1)10 (76.9)3 (21.4)11 (78.6)Vitamin D (ng/ml)Normal///0 (0.0)5 (100.0)0.30Insuffiency / Deficiency6 (26.1)17 (73.9)SARC-F (patients with 1 or 2 points)≥4 (sarcopenic)1 (5.9)16 (94.1)0.063 (16.7)15 (83.3)0.65< 4 (non sarcopenic)4 (36.4)7 (63.6)3 (27.3)8 (72.7)Mini-OQoL total score10: 351 (50,0)1 (50,0)2 (100,0)0 (0,0)0.1436 to 602 (12,5)14 (87,5)0.6311 (68,7)5 (31,3)61 to 702 (20,0)8 (80,0)10 (90,9)1 (9,1)
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as complete response disease for at least a year now.
Source: Abstract.
The patients were recruited from March 2018 to July 2020.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone damage after chemotherapy for lymphoma: a real-world experience
Observational study · BMC Musculoskeletal Disorders · 2021
Original publication title
Bone damage after chemotherapy for lymphoma: a real-world experience
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To provide further evidence of clinical or subclinical skeletal complications in correlation with biological variables and markers of bone disease in patients with complete response to therapy.
Source: AimAbstract: What methods does the paper describe?
A cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as complete response disease for at least a year now. We performed: blood chemistry tests, imaging techniques and screening tools for the assessment of functional status and quality of life (SARC-F and mini-Osteoporosis Quality of Life).
Source: MethodAbstract: Results
Approximately 50% of patients had osteoporosis, with a prevalence of vertebral fractures of 65.5%. In most patients, we found hypovitaminosis D and high levels of parathyroid hormone (PTH). Furthermore, a statistically significant association was observed between high PTH levels and previous lymphoma treatment. Finally, the Mini-Osteoporosis Quality of life (mini-OQLQ) questionnaire demonstrated a loss of quality of life as a consequence of the change in bone status.
Source: ResultsAbstract: Conclusions
Patient treatment design for personalized chemotherapy would be desirable to reduce late effects on bone. Also, early prevention programs need to be applied before starting treatment. The most benefited subpopulations could be not only elderly but also young patients.
Source: ConclusionsAuthors’ abstract
Background
Despite recent improvements in survival due to advances in treatment, the quality of life of patients with lymphoma may be compromised by the long-term complications of chemotherapy and steroid therapy. Among these, a potentially relevant problem is bone loss and the development of fragility fractures.
Aim
To provide further evidence of clinical or subclinical skeletal complications in correlation with biological variables and markers of bone disease in patients with complete response to therapy.
Method
A cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subsequent antineoplastic treatment, disease status after therapy defined as complete response disease for at least a year now. We performed: blood chemistry tests, imaging techniques and screening tools for the assessment of functional status and quality of life (SARC-F and mini-Osteoporosis Quality of Life).
Results
Approximately 50% of patients had osteoporosis, with a prevalence of vertebral fractures of 65.5%. In most patients, we found hypovitaminosis D and high levels of parathyroid hormone (PTH). Furthermore, a statistically significant association was observed between high PTH levels and previous lymphoma treatment. Finally, the Mini-Osteoporosis Quality of life (mini-OQLQ) questionnaire demonstrated a loss of quality of life as a consequence of the change in bone status.
Conclusions
Patient treatment design for personalized chemotherapy would be desirable to reduce late effects on bone. Also, early prevention programs need to be applied before starting treatment. The most benefited subpopulations could be not only elderly but also young patients.
Publication and source details
Original title: Bone damage after chemotherapy for lymphoma: a real-world experience
S. Mancuso; Dalila Scaturro; M. Santoro; G. Di Gaetano; F. Vitagliani; V. Falco; S. Siragusa; S. Gonnelli; G. Letizia Mauro
BMC Musculoskeletal Disorders · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T11:26:13.363208+00:00
DOI: 10.1186/s12891-021-04904-3 · PMC8653589